Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$21.22 USD
-0.83 (-3.76%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $21.04 -0.18 (-0.85%) 4:34 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BEAM 21.22 -0.83(-3.76%)
Will BEAM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BEAM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BEAM
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
Brian's Big Idea on Healthcare
BEAM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q4 Earnings and Revenue Estimates
Earnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to Decline
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
Other News for BEAM
Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics
Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Beam Therapeutics: A Strong Buy on Gene Editing Advancements and Strategic Growth Potential
Beam Therapeutics Stock (NASDAQ:BEAM): Investing in Cutting-Edge Gene Editing